ABOVE: COURTESY OF MD ANDERSON
Cancer therapy pioneer John Mendelsohn died from glioblastoma, an aggressive form of brain cancer, on Monday (January 7). He was 82. Mendelsohn was known for his development of a monoclonal antibody therapy now used to treat a number of different malignancies.
Mendelsohn was president emeritus of the University of Texas MD Anderson Cancer Center and held the position from 1996 to 2011. After stepping down as president, he took a six-month sabbatical, then returned to MD Anderson to co-lead the Sheikh Khalifa Bin Zayad Al Nahyan Institute for Personalized Cancer Therapy and also joined Rice University’s James A. Baker III Institute for Public Policy.
“Mendelsohn was a titan of the medical community who extended the lives of many threatened by cancer, a community leader who strove to make Houston a world class city, and a wonderful human being who spent a lifetime caring for others,” ...
